Aytu Biopharma (NASDAQ:AYTU) just posted results for its fiscal third quarter.
- Aytu reported a loss per share of $1.93. This was much worse than the analyst estimate for a loss per share of 63 cents.
- The company reported revenue of $22.73 million.
- This was also worse than the analyst estimate for revenue of $28 million.
- You can read the full Aytu press release here.
On the date of publication, Sarah Smith did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
Sarah Smith is the Editor-in-Chief of InvestorPlace.com.
